The present invention relates generally to the field of immunology and development of autologous vaccines. More specifically, the present invention is concerned with a method of treating autoimmune disease Multiple Sclerosis (MS) by means of immunizing patients with autologous CD8<；SUP>；+ <；/SUP>；cells activated with fragments of Myelin Basic Protein (MBP). The present invention identifies four immunogenic MBP fragments with high binding affinity to HLA-A2 and HLA-A24 receptors and discloses how to use these fragments in preparing anti-MS vaccine.
